N
BCTX

Natixis’s Briacell Therapeutics BCTX Stock Holding History

Natixis’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-149
Closed -$130K – 1020
2023
Q4 		$130K Sell
149
-488
-77% -$350K ﹤0.01% 755
2023
Q3 		$597K Buy
637
+35
+6% +$34.3K ﹤0.01% 579
2023
Q2 		$579K Buy
+602
New +$594K ﹤0.01% 618
2023
Q1 		– Sell
-83
Closed -$56.3K – 994
2022
Q4 		$56.3K Buy
+83
New +$70.3K ﹤0.01% 914

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Natixis's BCTX Position: Q1 2024 in Review

Natixis sold out of Briacell Therapeutics (BCTX) in Q1 2024, closing a stake of 149 shares — an estimated $130K sold.

Natixis first reported a position in BCTX in Q4 2022 and held it in 4 quarters. The position peaked at $597K in Q3 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q1 2024.

  • Natixis reported no remaining Briacell Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 149 Briacell Therapeutics shares in Q1 2024, an estimated $130K.
  • Natixis first reported a position in Briacell Therapeutics in Q4 2022 and held it in 4 quarters.
  • Natixis's Briacell Therapeutics position peaked at $597K in Q3 2023.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.